ESMO-Magnitude of Clinical Benefit Scale

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

The scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.

The ESMO-MCBS is an important first step to the critical public policy issue of value in cancer care, helping to frame the appropriate use of limited public and personal resources to deliver cost effective and affordable cancer care.

The ESMO-MCBS is a dynamic tool and its criteria revised on a regular basis.

ESMO 2018, Munich, Germany

The session 'ESMO-MCBS in perspective' will be taking place during the ESMO 2018 Congress in Munich, Germany on Friday 19 October 2018 at 14:00 - 15:30 in ICM - Room 14a all are welcome! 

For further information about ESMO-MCBS, please send an email to  mcbs@esmo.org

Introducing the ESMO Magnitude of Clinical Benefit Scale

Fortunato Ciardiello, Elisabeth de Vries, Josep Tabernero and Alexandru Eniu introduce The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) – a standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies.